Efficacy and safety of combination of Eribulin plus trastuzumab in patients with metastatic breast cancer in Spain

Trial Profile

Efficacy and safety of combination of Eribulin plus trastuzumab in patients with metastatic breast cancer in Spain

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Eribulin (Primary) ; Trastuzumab (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HALATRUST
  • Most Recent Events

    • 13 Oct 2017 New trial record
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top